GlassScriptPhysician profile
Mukesh Rao
NPI 1407929532
$864.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $32.57 · 2021: $103 · 2022: $258 · 2023: $79.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $238.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $142.72 | 2019-2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Glaxosmithkline, LLC. | $112.90 | 2019-2023 | Bexsero, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $81.75 | 2020-2022 | |
| Sanofi Pasteur INC. | $64.57 | 2019-2022 | |
| Corium, LLC | $52.37 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $32.14 | 2019-2020 | |
| Sobi, INC | $25.98 | 2022 | |
| Shire North American Group INC | $23.04 | 2019 | |
| Seqirus USA INC | $22.12 | 2022 | |
| Hologic Sales and Service, LLC | $18.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.42 | 2021 | |
| Tris Pharma INC | $15.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.